

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number
WO 01/06018 A1

(51) International Patent Classification⁶: C12Q 1/68, C07H 211/04, C12M 15/00

(74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).

(21) International Application Number: PCT/US00/00656

(22) International Filing Date: 11 January 2000 (11.01.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/357,073 19 July 1999 (19.07.1999) US

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).

Published:

— With international search report.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MONIA, Brett, P. [US/US]; 7605 Nueva Castilla Way, La Costa, CA 92009 (US). COWSERT, Lex, M. [US/US]; 3008 Newshire Street, Carlsbad, CA 92008 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/06018 A1

(54) Title: ANTISENSE MODULATION OF MAP KINASE KINASE 6 EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MAP kinase kinase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MAP kinase kinase 6. Methods of using these compounds for modulation of MAP kinase kinase 6 expression and for treatment of diseases associated with expression of MAP kinase kinase 6 are provided.

SEQUENCE LISTING

<110> Brett P. Monia
Lex M. Cowser
ISIS PHARMACEUTICALS, INC.

<120> ANTISENSE MODULATION OF MAP KINASE KINASE 6 EXPRESSION

<130> RTSP-0049

<150> US 09/357,073

<151> 1999-07-19

<160> 47

<210> 1

<211> 2924

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (341)..(1345)

<400> 1

ggcttctggt tcggcccacc tctgaagggt ccagaatcga tagtgaattc gtggttccaa	60
gtttggagct tttagctgcc agccctggcc catcatgtag ctgcagcaca gccttccta	120
acgttgcaac tgggggaaaa atcactttcc agtctgtttt gcaagggtgtg catttccatc	180
ttgattccct gaaagtccat ctgctgcac ggtcaagaga aactccactt gcatgaagat	240
tgcacgcctg cagcttgcat ctttgttgca aaactagcta cagaagagaa gcaaggcaaa	300
gtcttttgtg ctcccctccc ccatcaaagg aaaggggaaa atg tct cag tcg aaa	355
	Met Ser Gln Ser Lys
	1 5
ggc aag aag cga aac cct ggc ctt aaa att cca aaa gaa gca ttt gaa	403
Gly Lys Lys Arg Asn Pro Gly Leu Lys Ile Pro Lys Glu Ala Phe Glu	
	10 15 20
caa cct cag acc agt tcc aca cca cct aga gat tta gac tcc aag gct	451
Gln Pro Gln Thr Ser Ser Thr Pro Pro Arg Asp Leu Asp Ser Lys Ala	
	25 30 35
tgc att tct att gga aat cag aac ttt gag gtg aag gca gat gac ctg	499
Cys Ile Ser Ile Gly Asn Gln Asn Phe Glu Val Lys Ala Asp Asp Leu	
	40 45 50
gag cct ata atg gaa ctg gga cga ggt gcg tac ggg gtg gtg gag aag	547
Glu Pro Ile Met Glu Leu Gly Arg Gly Ala Tyr Gly Val Val Glu Lys	
	55 60 65

atg cgg cac gtg ccc agc ggg cag atc atg gca gtg aag cgg atc cga	595
Met Arg His Val Pro Ser Gly Gln Ile Met Ala Val Lys Arg Ile Arg	
70 75 80 85	
gcc aca gta aat agc cag gaa cag aaa cgg cta ctg atg gat ttg gat	643
Ala Thr Val Asn Ser Gln Glu Gln Lys Arg Leu Leu Met Asp Leu Asp	
90 95 100	
att tcc atg agg acg gtg gac tgt cca ttc act gtc acc ttt tat ggc	691
Ile Ser Met Arg Thr Val Asp Cys Pro Phe Thr Val Thr Phe Tyr Gly	
105 110 115	
gca ctg ttt cgg gag ggt gat gtg tgg atc tgc atg gag ctc atg gat	739
Ala Leu Phe Arg Glu Gly Asp Val Trp Ile Cys Met Glu Leu Met Asp	
120 125 130	
aca tca cta gat aaa ttc tac aaa caa gtt att gat aaa ggc cag aca	787
Thr Ser Leu Asp Lys Phe Tyr Lys Gln Val Ile Asp Lys Gly Gln Thr	
135 140 145	
att cca gag gac atc tta ggg aaa ata gca gtt tct att gta aaa gca	835
Ile Pro Glu Asp Ile Leu Gly Lys Ile Ala Val Ser Ile Val Lys Ala	
150 155 160 165	
tta gaa cat tta cat agt aag ctg tct gtc att cac aga gac gtc aag	883
Leu Glu His Leu His Ser Lys Leu Ser Val Ile His Arg Asp Val Lys	
170 175 180	
cct tct aat gta ctc atc aat gct ctc ggt caa gtg aag atg tgc gat	931
Pro Ser Asn Val Leu Ile Asn Ala Leu Gly Gln Val Lys Met Cys Asp	
185 190 195	
ttt gga atc agt ggc tac ttg gtg gac tct gtt gct aaa aca att gat	979
Phe Gly Ile Ser Gly Tyr Leu Val Asp Ser Val Ala Lys Thr Ile Asp	
200 205 210	
gca ggt tgc aaa cca tac atg gcc cct gaa aga ata aac cca gag ctc	1027
Ala Gly Cys Lys Pro Tyr Met Ala Pro Glu Arg Ile Asn Pro Glu Leu	
215 220 225	
aac cag aag gga tac agt gtg aag tct gac att tgg agt ctg ggc atc	1075
Asn Gln Lys Gly Tyr Ser Val Lys Ser Asp Ile Trp Ser Leu Gly Ile	
230 235 240 245	
acg atg att gag ttg gcc atc ctt cga ttt ccc tat gat tca tgg gga	1123
Thr Met Ile Glu Leu Ala Ile Leu Arg Phe Pro Tyr Asp Ser Trp Gly	
250 255 260	
act cca ttt cag cag ctc aaa cag gtg gta gag gag cca tcg cca caa	1171
Thr Pro Phe Gln Gln Leu Lys Gln Val Val Glu Glu Pro Ser Pro Gln	
265 270 275	
ctc cca gca gac aag ttc tct gca gag ttt gtt gac ttt acc tca cag	1219
Leu Pro Ala Asp Lys Phe Ser Ala Glu Phe Val Asp Phe Thr Ser Gln	
280 285 290	
tgc tta aag aag aat tcc aaa gaa cgg cct aca tac cca gag cta atg	1267
Cys Leu Lys Lys Asn Ser Lys Glu Arg Pro Thr Tyr Pro Glu Leu Met	
295 300 305	

```

caa cat cca ttt ttc acc cta cat gaa tcc aaa gga aca gat gtg gca 1315
Gln His Pro Phe Phe Thr Leu His Glu Ser Lys Gly Thr Asp Val Ala
310                      315                      320                      325

tct ttt gta aaa ctg att ctt gga gac taa aaagcagtgg acttaatcgg 1365
Ser Phe Val Lys Leu Ile Leu Gly Asp
330

ttgaccctac tgtggattgg tgggtttcgg ggtgaagcaa gttcactaca gcatcaatag 1425
aaagtcattct ttgagataat ttaaccctgc ctctcagagg gttttctctc ccaattttct 1485
ttttactccc cctcttaagg gggccttgga atctatagta tagaatgaac tgtctagatg 1545
gatgaattat gataaaggct taggacttca aaagggtgatt aaatatttaa tgatgtgtca 1605
tatgagtcct caagcttctc agacttctct tattctttac aaaatgaatg cattggccct 1665
gacaaaaagg tgctacggta gtgatgaaat tataagtaga tttgtagttt gtcccattta 1725
ttattttaat atttatgttt aagtgtttgg ttgaaaagat tccattttat acaagaaggg 1785
agattcaaaa aaaaaatata aggttggtt agcaatatat atagggcttt tattttttaa 1845
gttcaattgt gtctgtggtc cagaagaaat tatttaatat gcatctttga gaatattata 1905
aaaatatcaa aaaggagctc ttcttgtaga atgtctgttc cagctgttgt gactgctgcc 1965
atttttggaa acatctgccc aatcctgggt gatcaccaca tcttttaggg gaagtgacaa 2025
gatgctctgg tcatactctt tttcccaact ttggaaaaca taaaaatcac tcatataaca 2085
gctcaaagag taaaacattt gggtcttctg acacttgtagg tatagtatta gtggaaagtg 2145
at ttgtaata tgattttata tccacctacc tattcatcta cctgtgtgta tgtgtgtgtt 2205
tgtgtgtcta tttggcaatt cacaagtcct gccaaagtgg ttctatgagc atctctgttt 2265
ggtaaggagg acaattgtca gttttgaggg ggacatgtgt taaatcacag aaaaaaatgg 2325
tgccttcttc tgcgtttgtc cctcctgcca tgtgtaagtt gtaaggattg cttttgtagt 2385
taatgtactc tttggctttg tttgtttgtt ttcttcttca gtgaagcagc cttactattc 2445
atagaagggc tagaatagga gaaaatgaaa ggtagtgagt aattctttga taagatgagg 2505
aaataatggg aaagggtgaa ttaattcctg ggcattggact accagatgac cacaagttgc 2565
gttgaggccg catctttctt cagcagcgtg caatagctgg ctctctata ggagatgagc 2625
ttcattggga gttcctagca agttgactaa acagcaaaaag ttctttctcg tgggtaaata 2685
taccacacagg ttctatgatt tgtagctcta ggtttcttga tgatcaagga gtgaagtaat 2745
tgacagggaa aatatagacc tatgataaat aaccaggaag cattgctttt ggacaaggaa 2805
gaacagaggg ttttgatttt aaaaagaaga aaaaaaaacc ttattttttc tttcttggcc 2865
tcaagttcaa tatggagagg attgcttccc tgaatcctct cttccttccc cttttagag 2924

```

<210> 2
<211> 24
<212> DNA
<213> Artificial Sequence

<223> PCR Primer

<400> 2
aaaagaagca tttgaacaac ctca 24

<210> 3
<211> 25
<212> DNA
<213> Artificial Sequence

<223> PCR Primer

<400> 3
ttcacctcaa agttctgatt tccaa 25

<210> 4
<211> 34
<212> DNA
<213> Artificial Sequence

<223> PCR Probe

<400> 4
ttccacacca cctagagatt tagactccaa ggct 34

<210> 5
<211> 19
<212> DNA
<213> Artificial Sequence

<223> PCR Primer

<400> 5
gaaggtgaag gtcggagtc 19

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<223> PCR Primer

<400> 6
gaagatgggtg atgggatttc 20

<210> 7
<211> 20
<212> DNA

<213> Artificial Sequence

<223> PCR Probe

<400> 7

caagcttccc gttctcagcc

20

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 8

ggtgggccga accagaagcc

20

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 9

gccagggctg gcagctaaaa

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 10

gtttctcttg accgatgcag

20

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 11

tctgtagcta gttttgcaac

20

<210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 12
ttttcccctt tcctttgatg 20

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 13
cattttcccc ttctcttga 20

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 14
gacattttcc cctttccttt 20

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 15
gagacatttt cccctttcct 20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 16
ctgagacatt ttcccctttc 20

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 17
gactgagaca ttttcccctt 20

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 18
tcgactgaga cattttccccc 20

<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 19
tttcgactga gacattttcc 20

<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 20'
cctttcgact gagacatttt 20

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 21
tgcctttcga ctgagacatt 20

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 22
cttgcctttc gactgagaca 20

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 23

aattttaagg ccagggtttc

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 24

ttggagtcta aatctctagg

20

<210> 25

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 25

gctccaggtc atctgccttc

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 26

gtttctgttc ctggctatct

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 27

gccataaaaag gtgacagtga

20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 28

gaatttatct agtgatgtat

20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 29
cattagaagg cttgacgtct 20

<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 30
ggaaatcgaa ggatggccaa 20

<210> 31
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 31
tatgtaggcc gttctttgga 20

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 32
atctgttcct ttggattcat 20

<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 33
ttagtctcca agaatcagtt 20

<210> 34
<211> 20
<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 34

cttcacccccg aaaccaccca

20

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 35

cagttcattc tatactatag

20

<210> 36

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 36

ctacaaatct acttataatt

20

<210> 37

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 37

gatgcatatt aaataatttc

20

<210> 38

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 38

ccctaaaaga tgtggtgatc

20

<210> 39

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 39
caagtgtcag aagaaccaa 20

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 40
gtgaattgcc aaatagacac 20

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 41
acacatggca ggagggacaa 20

<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 42
agaagaaaac aaacaaacaa 20

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 43
tatcaaagaa ttactcacta 20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 44
cgctgctgaa gaaagatgcg 20

<210> 45
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 45
cgagaaagaa cttttgctgt 20

<210> 46
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 46
tattttccct gtcaattact 20

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 47
aagagaggat tcaggaagc 20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/00656

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/68; C07H 211/04; C12M 15/00

US CL : 435/6, 375, 91.1, 325, 366; 536/23.1, 24.31, 24.33, 24.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 375, 91.1, 91.3, 325, 366; 536/23.1, 23.2, 24.3, 24.31, 24.33, 24.5; 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, CAPLUS, LIFESCI, BIOSIS, WEST

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96/36642 A1 (DAVIS et al.) 21 November 1996 (21.11.99) , see entire document, especially figure 6 and pages 46-47.	1, 2, 5-19
Y	US 5,801,154 A (BARACCHINI et al.) 01 September 1998 (01.09.98), see columns 6-8.	1, 2, 5-19
Y	JAMES, W. Towards gene-inhibition therapy: a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozymes. Antiviral Chemistry & Chemotherapy. 1991, Vol. 2, Number 4, pages 191-214, especially page 198.	1, 2, 5-19

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

09 MARCH 2000

Date of mailing of the international search report

06 APR 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KAREN A. LACOURCIERE

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US00/00656**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MILNER, N. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nature Biotechnology. 15 June 1997 (15.06.97) Vol. 15, pages 537-541, see entire document.	1, 2, 5-19